



Identification of New Therapeutic Targets for Gastric Cancer With Bioinformatics

Yang Li¹, Jin-Shen Wang¹, Tao Zhang², Hong-Chang Wang¹ and Le-Ping Li^{1*}

¹ Department of Gastrointestinal Surgery, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China, ² Department of Biostatistics, School of Public Health, Shandong University, Jinan, China

We aimed to identify new targets affecting gastric cancer (GC) prognosis. Six target genes were identified from hub genes based on their relationship with important factors affecting tumor progression, like immune infiltration, purity, tumor mutation burden (TMB), and tumor microenvironment (TME) score. The effect of target genes' somatic mutations and copy number alteration (CNA) was examined to determine their effect on GC prognosis. Six target genes (FBN1, FN1, HGF, MMP9, THBS1, and VCAN) were identified. Reduced expression of each target gene, except MMP9, indicated better prognosis and lower grade in GC. FBN1, THBS1, and VCAN showed lower expression in stage I GC. Non-silencing mutations of the six genes played a role in significantly higher TMB and TME scores. THBS1 mutation was associated with earlier stage GC, and VCAN mutation was associated with lower grade GC. However, patients with target gene CNA displayed higher tumor purity. MMP9, THBS1, and VCAN CNA was associated with lower grade GC, while FBN1 CNA reflected earlier T stage. Additionally, the target genes may affect GC prognosis by influencing multiple oncogenic signaling pathways. FBN1, FN1, HGF, MMP9, THBS1, and VCAN may be new GC prognostic targets by affecting tumor purity, TMB, TME score, and multiple oncogenic signaling pathways.

OPEN ACCESS

Edited by:

Pietro Zoppoli, Oncological Center of Basilicata (IRCCS), Italy

Reviewed by:

Sabino Russi, Oncological Center of Basilicata (IRCCS), Italy Mulong Du, Nanjing Medical University, China

> *Correspondence: Le-Ping Li lepingdoctor@126.com

Specialty section:

This article was submitted to Cancer Genetics, a section of the journal Frontiers in Genetics

Received: 04 June 2020 **Accepted:** 16 July 2020 **Published:** 18 August 2020

Citation:

Li Y, Wang J-S, Zhang T, Wang H-C and Li L-P (2020) Identification of New Therapeutic Targets for Gastric Cancer With Bioinformatics. Front. Genet. 11:865. doi: 10.3389/fgene.2020.00865 Keywords: gastric cancer, prognosis, mutation, CNA, purity, TMB, TME score

INTRODUCTION

Gastric cancer (GC) is a disease with a high incidence and high mortality around the world (Kamangar et al., 2006). With the development of medical technology, treatment of GC with surgery combined with chemoradiotherapy is gradually becoming more effective, but the 5-year survival rate remains subpar (Ferlay et al., 2015; Li Y. et al., 2019). In particular, post-operative chemotherapy has a major impact on the prognosis and survival of GC patients

1

Abbreviations: 5-FU, 5-Fluorourac; CCLE, Cancer Cell Line Encyclopedia; CNA, Copy Number Alteration; GC, Gastric Cancer; GDSC, Genomics of Drug Sensitivity in Cancer; GO-BP, Gene Ontology Biological process; GTEx, The Genotype-Tissue Expression; KM, Kaplan-Meier; STAD, Stomach Adenocarcinoma; TCGA, The Cancer Genome Atlas; TMB, Tumor Mutation Burden; TME, Tumor Microenvironment.



(Kunkler, 1994; van de Velde, 2008; Bernini and Bencini, 2012). In recent years, a variety of regimens have been studied to identify an improved therapeutic approach. However, treatment can vary greatly in patients with the same pathological type and stage, or even in those with similar expression of hub genes (Yan et al., 2018; Huang et al., 2019). Therefore, it is important to identify new targets influencing the prognosis of GC.

Immune infiltration, tumor purity, tumor mutation burden (TMB), and tumor microenvironment (TME) score have been investigated as important factors affecting tumor prognosis and chemoradiotherapy (Yoshihara et al., 2013; Aran et al., 2015; Hellmann et al., 2018; Lazar et al., 2018; Zeng et al., 2018; Pan et al., 2019). Higher TMB, TME score, and tumor purity indicate a better prognosis. Somatic mutations and copy number alterations (CNAs) of genes are also key factors affecting tumor development through complex mechanisms (Cutcutache et al., 2016; Liang et al., 2016; Li et al., 2018; Li X. et al., 2019). Large-scale studies have aimed to explore the molecular changes in GC that may reveal new and important targets in its therapy.

In our study, we analyzed the Cancer Cell Line Encyclopedia (CCLE), The Cancer Genome Atlas (TCGA), and the Genomics of Drug Sensitivity in Cancer (GDSC) database, to select six

genes (*FBN1*, *FN1*, *HGF*, *MMP9*, *THBS1*, and *VCAN*) as target genes. Based on their expression, mutation, and CNA, along with analysis of their relationship with clinical information, TMB, TME score, tumor purity, immune infiltration, and classic oncogenic signaling pathways, we thought that these genes could serve as new therapeutic and prognostic targets (**Figure 1**).

MATERIALS AND METHODS

Data Collection and Hub Gene Selection

RNA-seq data from gastric cells was downloaded from the CCLE database¹. 5-FU and oxaliplatin drug sensitivity for different gastric cancer cell lines were obtained from the GDSC database². Primary somatic mutation, RNA-seq, and clinical data from TCGA Stomach Cancer (STAD) was downloaded from TCGA³. GEPIA2⁴ was used for the comparison of gene expression

¹https://portals.broadinstitute.org/ccle

²https://www.cancerrxgene.org/

³https://www.cancer.gov/

⁴http://gepia2.cancer-pku.cn/#index



between 5FU-sensitive and non-sensitive cells, (**B**) heat map of differentially expressed genes in Oxaliplatin groups, (**C**) GO analysis of downregulated genes revealed that these genes were primarily involved in the negative regulation of endopeptidase activity, cell adhesion, inflammatory response, extracellular matrix organization, etc., (**D**) upregulated genes were primarily involved in positive and negative regulation of transcription from RNA polymerase II promoter, negative regulation of apoptosis, chemical synaptic transmission, etc.

between STAD and normal tissue from GTEx dataset. MC3 gene-level non-silent mutation data and gistic2 threshold of copy number data was obtained from UCSC Xena website⁵. The EdgeR package was used to analyze differential gene expression (P < 0.05, $|\log FC| \ge 1$). Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) were analyzed using DAVID⁶. The protein interaction network was constructed in String⁷. Using 12 algorithms and a combination of the most commonly used methods (Degree and MCC) referenced

elsewhere (Chin et al., 2014; Wang W. et al., 2019), we selected the top 30 hub genes using cytohubba in Cytoscape (version 3.7.1).

Calculation of Immune Infiltration, Tumor Purity, TMB, and TME Score

The immune cells portion was calculated using the CIBERSORTS⁸ method and the LM22 gene signature were used for immune infiltration analysis (Chen et al., 2018). All results were considered statistically significant if P < 0.05. Correlation between immune cells and hub genes was calculated

⁵https://xena.ucsc.edu/

⁶https://david.ncifcrf.gov/

⁷https://string-db.org/

⁸https://cibersort.stanford.edu/





4



by Pearson (| R | > 0.4 and P < 0.05). TMB was calculated based on somatic mutation data. TME score was calculated as previously described (Zeng et al., 2019). Tumor purity, immune score, and stromal score were calculated using the ESTIMATE package (Yoshihara et al., 2013). The best cut-off values of genes for Kaplan-Meier were calculated by survminer package through R software (Li M. et al., 2019). Ten classic oncogenic signaling pathways and important genes among them were from Sanchez-Vega et al. (2018).

Statistical Analysis

Statistical analyses were conducted using R software (3.6.1 version) and SPSS version 23.0. Graphical representations were generated using GraphPad Prism 8. Mann-Whitney test and Kruskal-Wallis tests were used for continuous variables with two or more groups, respectively. Chi squared was used for categorical variables. The Pearson coefficient was used to test for correlations.

RESULTS

Differential Gene Expression and Hub Genes

From the GDSC database, genes were analyzed for differences in expression between sensitive and drug-resistant cells of 5-Fluorouraci (5-FU) and Oxaliplatin, respectively. Comparing sensitive and drug-resistant cells revealed 328 and 84 differentially expressed genes, respectively (16 duplicate genes) (Figures 2A,B and Supplementary Table S1). Gene Ontology Biological process (GO-BP) analysis showed that the differentially expressed genes were primarily involved in negative regulation of endopeptidase activity, cell adhesion, inflammatory response, and O-glycan processing (Figures 2C,D). These biological functions are closely related to the development and prognosis of GC (Duarte et al., 2016; Cui et al., 2017; Mukai et al., 2017; Geng et al., 2018).

Selection of Hub Genes

All differentially expressed genes were used in the String website to construct a protein interaction network, and key hub genes were identified by cytohubba in Cytoscape. Thirty hub genes were selected using 12 algorithms (**Supplementary Table S2**) and combined the most frequent methods (Degree and MCC) referenced in other studies. The expression levels of the 30 hub genes in TCGA Stomach adenocarcinoma (TCGA-STAD) and normal tissue from GTEx dataset were got from GEPIA2 (**Figure 3**). It showed that 10 genes (AGT, FN1, ERBB2, FBN1, IGF2, MMP9, SERPINA1, SPP1, VCAN and SERPINE1) were significantly higher expressed in tumor tissues, while 3 genes including APOA1, FGG, and TTR, were significantly lower expressed in tumor tissues.

Correlation Between Hub Genes and Immune Infiltration

The correlation between mRNA expression of the 30 hub genes and 22 immune cell types is shown in **Figure 4B**. Naive T cells were not considered due to lack of expression



in almost all patients, prohibiting any comparisons. mRNA expression of *MMP9* and *SPP1* showed a high positive correlation with Macrophage M0 cells (**Figure 4A**). mRNA expression of IL1B showed a high positive correlation with activated mast cells and neutrophils. In contrast, mRNA expression of *MMP9* showed a negative correlation with resting mast cells. The correlation between the expression of other hub genes and immune cell types was low (between 0 and 0.4). Therefore, we assumed that mRNA expression level of other hub

genes, other than those mentioned above, had little correlation with immune cells.

Correlation Between Hub Genes and TMB, TME Score, Tumor Purity, Immune Score, and Stromal Score

Among the 30 hub genes, six genes (*FBN1*, *FN1*, *HGF*, *MMP9*, *THBS1*, and *VCAN*) were negatively correlated with tumor purity



target genes in the CNA and non-CNA group, (C) expression of the six target genes in different CNA subtype group. ***P < 0.005; **P < 0.01; *P < 0.05.

and TME score, and positively correlated with tumor immune score and stromal score (**Figure 5B**). Therefore, we selected these six genes as target genes. **Figure 5A** shows how target gene expression changes based on tumor purity and TME score. This is consistent with the results in **Figure 5B**, indicating that lower mRNA expression of target genes is associated with higher tumor purity and TME score, and lower immune and stromal scores.

Correlation Between Target Gene Mutations and TMB, TME Score, Tumor Purity, Immune Score, and Stromal Score

Figure 6A shows that *APOB*, *FBN1*, *VCAN*, *FN1*, *ERBB2*, *HGF*, *THBS1*, and *MMP9* have high mutation frequencies. These genes typically harbor missense mutations. Except for *APOB* and *ERBB2*, the remaining genes were the target genes selected above, which were highly related to tumor purity, TME score, immune score, and stromal score. **Figure 6B** shows that there were no significant differences in mRNA expression, tumor purity, immune score, or stromal score between the mutated and wild type genes. However, the TMB and TME scores in the mutated target genes were significantly higher than those in the non-mutated genes. This suggests that GC patients with target gene mutations could displayed higher TMB and TME score.

Correlation Between CNA of Target Genes and TMB, Tumor Purity, TME Score, Immune Score, and Stromal Score

Unlike mutations, the 30 hub genes had significantly higher rates of CNA, with each gene occurring in approximately a third or more of the patients (**Figure 7A**). We also divided the CNA group and non-CNA group for analysis. Four target genes (*FBN1*, *HGF*, *THBS1*, and *VCAN*) had significantly lower mRNA expression in the CNA group (**Figure 7B**). For further analysis, we compared the mRNA expression in different subgroup (**Figure 7C**). When single copy deletion occurred, the expression of FBN1, HGF, THBS1, and VCAN decreased. While for FBN1 and THBS1, the expression also decreased when low amplification occurred. Maybe heterogeneity or unusual behavior of these patients affected the expression of genes. Other types of CNA seemed no impact on the expression of the genes. No matter amplification or deletion, the variation trend of genes expression reflected in **Figure 7C** was consistent with that in **Figure 7B**.

Single-copy number deletions and low-fold amplifications were the major types of CNA found for the target genes. Tumor purity was higher in the CNA group than that in the non-CNA group (**Figure 8A**), and their stromal and immune scores were significantly lower than those in the non-CNA group



(Figures 8B,C). A similar trend was found for all six target genes. There was no significant difference in TMB or TME score between the CNA and non-CNA groups (Figures 8D,E). This suggests that the CNA of target genes may significantly affected the purity of the tumor.

Correlation Between Target Genes and Clinical Information

We analyzed the relationship between target gene mRNA expression level and clinical stage and grade. The expression of *FBN1, THBS1*, and *VCAN* had a significant relationship with stage (**Figure 9A**), and each had reduced expression in stage1. Regarding grade, all target genes except *MMP9* had significant relationships with grade, especially between grade 2 and 3 (**Figure 9B**). This indicated that lower expression of target genes was associated with earlier stages and lower grades. Regarding survival (**Figure 9C**), all target genes except *MMP9* were found to be prognostic factors by univariate cox analysis; lower expression indicated better prognosis.

As shown in **Table 1**, most patients in the *FN1* mutation group were female, and those with *THBS1* mutations had a relatively earlier clinical stage. Other gene mutations were not clinically relevant. Patients with *VCAN* mutations appeared to have a lower grade compared to patients without *VCAN* mutations.

Besides, we also compared the clinical characteristics in CNA subgroup (**Supplementary Table S3**). However, the small sample size in some group made the comparison less accurate, so we divided the patients into CNA and non-CNA group. As shown

in **Table 2**, the number of male patients with *MMP9* CNA was higher than the number of female patients, and patients with *MMP9* CNA showed a lower grade. In addition, patients with *THBS1* CNA or *VCAN* CNA also showed lower grades.

Additionally, we analyzed the prognosis with respect to target genes in the mutant and wild type groups, and CNA and non-CNA group; however, there were no significant differences (**Figure 10** and **Supplementary Table S3**). This indicates that the mutation or CNA of target genes is associated with an earlier stage or grade, especially for *THBS1*, *VCAN*, *FBN1*, and *MMP9*.

Target Genes and 10 Classic Oncogenic Signaling Pathways

Sanchez-Vega et al. (2018) showed that 10 oncogenic signaling pathways are altered in the TCGA pan-cancer atlas. The pathways were considered altered if any key pathway gene was changed (Sanchez-Vega et al., 2018). Here we cited the data of signaling pathways and gene alteration in the article, and explored the relationship between our target genes and these pathways. Indeed, the classic oncogenic pathways were found to be altered in different groups with respect to the mutation and CNA of our target genes.

Figures 11A,B shows that the mutation of target genes seemed to have no effect on the TP53 or MYC pathway. Mutations in all target genes displayed higher alterations in the HIPPO pathway. With exception of *HGF*, the mutation of target genes also showed higher alterations in the WNT, PI3K, and NOTCH pathways. In addition, mutation of *FBN1* and *MMP9* reflected



higher alterations in the TGF pathway. Mutation of *FBN1* and *FN1* showed increased alterations of the RTK-RAS pathway. Mutation of *FN1* showed increased alteration in NRF2 pathway. For *HGF* mutation, other than the HIPPO pathway, only the Cell cycle pathway had reduced alteration.

Figures 11C,D shows that when CNA occurred in any of the target genes, the altered ratio of the TP53 pathway significantly increased while the altered ratio of the NOTCH pathway significantly decreased. In addition, alteration of the RAS pathway seemed to increase with the CNA of *HGF*, *THBS1*, and *FBN1*. Alteration of Cell cycle pathway also increased with the CNA of *VCAN* and *MMP9*. The CNA of *FN1*, *THBS1*, *VCAN*, and *MMP9* reflected a decreased alteration of the WNT pathway. CNA of MMP9 displayed a decreased alteration in the TGF pathway and HIPPO pathway. CNA of *FBN1* showed a reduced alteration in the HIPPO pathway. PI3K, NFR2, and MYC signaling pathways showed no significant alterations with the CNA of target genes.

This indicated that the CNA of target genes seemed to have more influence on the WNT, TP53, and NOTCH pathways. However, the mutation of target genes may have more influence on the WNT, PI3K, NOTCH, and HIPPO pathways. Taken together, these results showed that changes in the target genes could affect multiple signaling pathways.

Co-occurrence and Mutual Exclusivity Between Target Genes and Pathway Genes

Figure 12 shows the co-occurrence and mutual exclusivity between target genes and 187 genes from 10 pathways. Target genes exhibited co-occurrence with the key genes in these pathways and no significant mutual exclusivity (**Supplementary Table S4**). In addition, *FN1* and *FBN1* showed more co-occurrence with pathway genes, particularly from the NOTCH and HIPPO pathways. The other target genes also tended to co-occurr with genes in the NOTCH and HIPPO pathways. Among the target genes, *FBN1* most often co-occurred with *FN1* and *VCAN*. *MMP9* most often co-occurred with *VCAN*. *HGF* and *THBS1* have little co-occurrence with other genes (**Supplementary Table S4**).

	Mutation of	target	denes	and	clinical	characteristics
IADEE I	inducation of	larger	yenes .	anu	omnoar	0110100101001003.

Characteristics		FBN1			FN1		HGF			
	w	m	Р	w	m	Р	w	m	Р	
 T1	22	1	0.267	21	2	0.360	21	2	0.069	
Т2	86	6		85	7		87	5		
ТЗ	183	15		190	8		195	3		
Τ4	102	15		107	10		109	8		
T1+2	108	7	0.261	106	9	0.424	108	7	0.234	
T3+4	285	30		297	18		304	11		
NO	121	12	0.677	123	10	0.582	125	8	0.769	
N1	109	8		109	8		112	5		
N2	76	9		78	7		82	3		
N3	77	10		84	3		84	3		
N0+1	230	20	0.288	232	18	0.574	237	13	0.405	
N2+3	153	19		162	10		166	6		
MO	353	34	0.404	363	24	0.668	370	17	0.848	
M1	26	4		27	3		29	1		
Stage1	55	4	0.563	53	6	0.305	53	6	0 109	
Stage?	127	9	0.000	131	5	0.000	132	4	0.100	
Stage3	164	19		171	12		177	6		
Stage/	30	5		40	12		42	2		
Stage1 + 2	192	12	0 157	19/		0.556	195	10	0.416	
Stage? + 4	202	13	0.137	011	16	0.000	210	0	0.410	
Stages+4	203	24	0 504	211	10	0.641	219	0	0.650	
GI	110	10	0.524	147	0	0.641	11	і Г	0.650	
G2	140	18		147	11		153	5		
G3	239	21	0.500	243	17	0.0001	250	10	0.007	
Female	142	16	0.580	141	17	0.009*	151	7	0.937	
Male	257	24		269	12		269	12		
Characteristics		MMP9			THBS1			VCAN		
	w	m	Р	w	m	Р	w	m	Р	
 T1	22	1	0.644	21	2	0.573	20	3	0.421	
Т2	87	5		88	4		83	9		
ТЗ	193	5		190	8		187	11		
Τ4	112	5		114	3		108	9		
T1+2	109	6	0.322	109	6	0.416	103	12	0.153	
T3+4	305	10		304	11		295	20		
NO	127	6	0.573	125	8	0.242	119	14	0.376	
N1	112	5		111	6		108	9		
N2	82	3		84	- 1		80	5		
N3	86	1		85	2		83	4		
NO+1	239	11	0.258	236	14	0.084	227	23	0 130	
N2+3	168	1	0.200	169	3	0.004	163	9	0.100	
M0	370	17	0.624	271	16	0.619	356	21	0.030	
	30	0	0.024	30	0	0.018	00	0	0.930	
Oteccel	50	0	0.445	50	0	0.000	20	2	0.007	
Stage	57	2	0.445	55	4	0.229	54	5	0.327	
Stagez	129	7		128	8		122	14		
Stage3	177	6		179	4		174	9		
Stage4	44	0	0.075	43	1	0.040*	41	3		
Stage1+2	186	9	0.275	183	12	0.040*	176	19	0.118	
Stage3+4	221	6		222	5		215	12		
G1	11	1	0.228	12	0	0.161	9	3	0.023*	
G2	149	9		155	3		142	16		
G3	253	7		246	14		245	15		
Female	150	8	0.332	150	8	0.332	141	17	0.076	
Male	272	9		272	9		264	17		

*Indicates p < 0.05; "w" meant wild type group; "m" meant mutated group.

TABLE 2 | CNA of target genes and clinical characteristics.

Characteristics	FBN1				FN1		HGF		
	n	с	Р	n	с	Р	n	с	Р
 T1	15	4	0.076	11	8	0.065	8	11	0.321
T2	49	31		63	17		41	39	
ТЗ	104	63		109	58		77	90	
T4	75	25		75	25		57	43	
T1+2	64	35	0.667	74	25	0.277	49	50	0.906
T3+4	179	88		184	83		134	133	
NO	81	31	0.208	76	36	0.540	54	58	0.253
N1	65	32		73	24		56	41	
N2	43	32		54	21		32	43	
N3	49	25		49	25		37	37	
N0+1	146	63	0.109	149	60	0.658	110	99	0.238
N2+3	92	57		103	46		69	80	
MO	222	107	0.535	233	96	0.765	161	168	0.286
M1	16	10	0.000	17	8	0.100	15	10	0.200
Stage1	35	18	0.350	36	17	0.851	24	29	0 702
Stage?	80	30	0.000	75	35	0.001	55	55	0.102
Stage3	93	57		109	41		75	75	
Stage/	25	13		27	11		22	16	
Stage1+2	115	18	0 124	111	52	0 385	70	84	0 559
Stage? 4	119	40	0.124	126	52	0.565	07	04	0.009
C1	7	2	0.056	0	0	0 160	91	91	0.206
	1	5	0.250	0	2	0.102	4	76	0.300
G2	150	53		69 161	40		114	104	
Go	152	00	0.005	101	57	0.150	74	104	0.000
Female	88	46	0.825	89	45	0.158	74	60	0.096
Male	161	79		176	64		111	129	
Characteristics		MMP9			THBS1			VCAN	
	n	с	Р	n	с	Р	n	с	Р
T1	5	14	0.620	13	6	0.180	10	9	0.212
T2	25	55		95	32		47	33	
Т3	50	117		105	62		87	80	
T4	37	63		70	30		65	35	
T1+2	30	69	0.678	108	38	0.078	57	42	0.912
T3+4	87	180		175	92		152	115	
NO	41	71	0.433	78	34	0.190	67	45	0.473
N1	27	70		65	32		50	47	
N2	21	54		41	34		41	34	
N3	26	48		47	27		46	28	
N0+1	68	141	0.83	143	66	0.068	117	92	0.650
N2+3	47	102		88	61		87	62	
MO	105	224	0.673	214	115	0.916	185	144	0.450
M1	9	16		16	9		16	9	
Stage1	16	36	0.663	34	19	0.336	31	22	0.665
Stage2	39	71		79	32		60	50	
Stage3	45	109		91	59		84	66	
Stage4	14	24		23	15		25	13	
Stage1+2	55	107	0.518	113	51	0.106	91	72	0.685
Stage3+4	59	133	0.010	114	74	0.100	109	79	0.000
G1	1	10	0*	7	3	0.023*	7	3	∩*
62	21	106	0	76	62	0.020	58	70	U
63	о I Q Л	124		151	67		1/1	77	
Eomalo	54	104	0.000*	101	07 مر	0 800	01	11	0 070
Mala	54	175	0.009	151	41	0.000	10	100	0.272
IVIAIE	CO	1/5		154	QD		151	109	

*Indicates p < 0.05; "n" meant non-CNA group; "c" meant CNA group.



FIGURE 10 | KM of target genes with mutation or CNA. (A) KM survival between the CNA and non-CNA group of target genes, (B) KM survival between the mutated and wild type group of target genes.

Together, these results indicated that the target genes always exhibited co-occurrence in GC, especially *FBN1*, *FN1*, and *VCAN*. The target genes exhibited more co-occurrence with key genes in the NOTCH and HIPPO pathways than other pathways.

DISCUSSION

GC is a common malignant tumor with various factors causing high mortality rates and a low ratio of 5-year survival. Different treatment regimens have been adopted for GC patients at different stages. Even patients with the same pathological type, the outcomes of surgery and post-operative chemotherapy will be very different. Therefore, it has been urgent find new factors and targets in GC. In our study, we combined the GDSC, CCLE, and TCGA database to identify six new target genes (*FBN1*, *FN1*, *HGF*, *MMP9*, *THBS1*, and *VCAN*). A few of articles reflected that some indexes could affect the proliferation and invasion of GC by regulating HGF or MMP9 (Appleby et al., 2017; Matsumoto et al., 2017; Zhang et al., 2017; Ding et al., 2018; Wang R. et al., 2018), but the function of these six genes in GC was still not well-known, especially *FBN1*, *FN1*, and *VCAN* (Lee et al., 2016; Sakai et al., 2016; Wang J. et al., 2018; Jiang et al., 2019). By observing the relationships between target genes and important factors that have proven to affect the treatment and prognosis of GC, such as immune infiltration, tumor purity, TMB, TME score,

		121	94	196	199	137	4	122	,	60 🗖	67	2	27	346
	FBN1-nonmut					_								~
	FBN1-mut	22	16	22	29	22	2	28	3	9	18		25	37
	VCAN-nonmut	125	99	202	207	141	6	130)	60 🗖	71	2	37	353
	VCAN-mut	18	11	16	21	18	0 🛽	20)	9	14		15 🔳	30
	HGF-nonmut	132	104	205	217	148	5	139) 🗖	67 🗖	75	2	45	364
	HGF-mut	1 11	6	13	11	111	11	11	1	2	10		7 🔳	19
	THBS1-nonmut	133	103	210	218	148	6	135	5 🗖	68 🔲	73	2	40	367
	THBS1-mut	10	71	8	10	1 11	0	15	5	1	12		12	16
	FN1-nonmut	127	100	204	208	144	4	132		63	74	2	36	360
	EN1_mut	16	10	14	20	15	2	19		6	11		16	23
	MMD0 popmut	122	101	207	20	140	5	140		67	77			270
	MMP9-mut	10	91	11	10	10	1	10)	2	8		9	13
P	Dereentere		Data	TDE2		ו אנום			MAN					ananla numbar
0	Fercentage	25%	Dela	570/	590/		10/	250			100/	Cell.Cyc		
		50%	21%	50%	30%	40%	F 0/	33%		1 70	1970	00	20/	340
	FBIN1-mut	*** 59% *	43%	59%	* /0%	*59%	5%	*** /0%		4% **	* 49%	00	5%	37
	VCAN-nonmut	35%	28%	57%	59%	40%	2%	31%		1%	20%	6	/%	353
	VCAN-mut	** 60%	37%	53%	70%	*60%	0%	*** 67%	0 3	0% **	*4/%	50	J%	30
	HGF-nonmut	36%	29%	56%	60%	41%	1%	38%		8%	21%	67	/%	364
	HGF-mut	58%	32%	68%	58%	58%	5%	58%		1% **	* 53%	** 37	7%	19
	THBS1-nonmut	36%	28%	57%	59%	40%	2%	37%	1	9%	20%	6	5%	367
	THBS1-mut	* 63%	44%	50%	63%	*69%	0%	*** 94%		6% ォ	×75%	75	5%	16
	FN1-nonmut	35%	28%	57%	58%	40%	1%	37%	6 1	8%	21%	66	5%	360
	FN1-mut	***70%	43%	61%	* 87%	*65%	* 9%	*** 78%	2	6% **	* 48%	70	2%	23
	MMP9-nonmut	36%	27%	56%	59%	40%	1%	38%	1	8%	21%	66	5%	370
		++ 770/		0507	770/			770	1	50/	620/	6	2%	13
С	Number FN1-noncna FN1-cna VCAN-poncna	WNT TC 112 31	 ↔ 69% ↔ 69%	TP53	RTK.RA	×77% S PI3K 9 ■118 9 ■ 41 2 ■ 96	8% NRF2	• 71%	H N 23 27	AYC 48 21 33	HIPPC) Cell.C 3	ycle 76 132	Sample number 27 10 22
С	Number FN1-noncna FN1-cna VCAN-noncna VCAN-cna HGF-noncna HGF-cna THBS1-noncna FBN1-cna FBN1-cna MMP9-noncna MMP9-cna	WNT TC 12 31 94 49 75 68 104 39 105 38 58 85	GF-Beta 69% 67-Beta 86 24 70 56 54 79 31 77 33 51 59	TP53 139 79 94 24 83 15 19 99 24 94 51 167	RTK.RA 15 6 13 9 13 13 9 13 9 13 9 13 9 13 9 13 13 9 13 13 9 13 13 9 13 13 13 13 13 13 13 13 13 13	S PI3K 9 1 18 9 1 41 2 9 96 6 6 63 8 8 83 0 76 4 11 4 4 4 8 11 0 48 8 11 0 48 6 56 2 1 03	8% NRF2 3 5 4 5 4 5 4 1 5 3 1 5 4 5 4 5 4 5 4 5 4 5 4 5 4 5 4 6 2 3 4	NOTC	H N 23 27 07 43 89 61 21 29 24 26 69 81	AYC 48 21 33 36 32 37 45 24 45 24 47 22 22 47	HIPPC 6 1 2 5 1 2 4 4 6 1 2 6 1 2 6 1 2 6 1 2 4 4 4 4 4 4 4 4 4 4 4 4 4	Cell.C 3 2 6 9 1 2 3 2 0 0 0 5 0 0 5	Eycle 76 76 132 120 133 157 95 164 88 72	Sample number 27 10 22 16 19 19 25 13 25 13 25 12 12 25 25 21 25 25 25 25 25 25 25 25 25 25 25 25 25
C	Number FN1-noncna FN1-cna VCAN-noncna VCAN-cna HGF-noncna HGF-cna THBS1-cna FBN1-cna FBN1-cna FBN1-cna MMP9-noncna MMP9-cna Percentage	WNT TC	GF-Beta GF-Beta 6 6 6 6 6 6 6 6 6 6 6 6 6	TP53 39 79 94 24 83 33 33 33 51 99 99 24 94 51 167 TP53	RTK.RA 15 6 13 9 13 13 9 13 13 9 13 7 15 RTK.RA	S PI3K 9 14 9 41 6 6 63 8 83 0 76 4 11 4 48 8 11 4 48 8 11 0 48 6 56 2 0 03 S PI3K	8% NRF2 1 1 5 3 3 2 5 4 1 5 3 1 2 5 4 1 5 3 1 1 5 2 3 1 4 5 2 3 1 4 5 2 3 1 4 5 3 1 4 5 1 5 5 1 4 5 1 5 5 1 1 5 5 1 1 5 5 1 1 5 5 1 1 1 1		H N 23 27 07 43 89 61 21 29 24 26 81 81 81	AYC 48 21 33 36 32 37 45 24 47 22 22 47 47	HIPPC HIPPC HIPPC HIPPC HIPPC HIPPC	 Cell.C Cell.C Cell.C Cell.C Cell.C 	Sycle 76 76 132 120 119 133 157 95 164 88 72 180 Sycle	Sample number 27 10 22 16 19 25 13 25 13 25 12 12 25 Sample number
C	Number FN1-noncna FN1-cna VCAN-noncna VCAN-cna HGF-noncna HGF-cna THBS1-noncna FBN1-noncna FBN1-cna MMP9-noncna MMP9-cna Percentage FN1-noncna	WNT TC 112 31 94 49 75 68 104 39 105 38 58 85 WNT TC 40%	GF-Beta 26 26 27 30 50 54 54 54 54 54 54 54 51 51 59 6F-Beta 31%	TP53 39 79 24 24 83 35 19 99 24 54 50%	RTK.RA 6 13 9 9 13 9 13 9 13 9 13 9 13 9 13 15 RTK.RA	S PI3K 9 1 18 9 1 41 2 96 6 6 38 8 83 0 7 76 4 11 4 4 48 8 11 0 48 6 56 2 0 3 5 PI3K % 43%	8% NRF2 3 5 3 5 3 5 3 5 3 5 3 6 4 5 7 5 7 5 7 5 7 5 7 5 7 5 7 5 7 5 7 5 7	NOTC	H N 23 27 07 43 89 61 21 29 24 26 81 29 81 29 81 50 81	AYC 48 21 33 36 37 45 24 47 22 1 47 22 1 47 MYC 17%	HIPPC HI	 Cell.C 3 2 6 9 4 1 3 2 5 5 6 6 1 <	ycle 76 76 76 10 120 119 133 157 95 164 88 72 180 Sycle 64%	Sample number 27 10 22 16 19 25 13 25 13 25 25 25 25 25 25 25 25 25 25
D	Number FN1-noncna FN1-cna VCAN-cna HGF-noncna HGF-cna THBS1-oncna FBN1-noncna FBN1-cna MMP9-noncna MMP9-cna Percentage FN1-noncna FN1-cna	WNT TC 112 31 94 49 75 68 104 39 105 38 58 85 WNT TC 40% 29%	GF-Beta 69% 64 64 64 64 70 40 56 54 79 31 77 33 51 59 6F-Beta 31% 23%	TP53 139 79 94 24 83 199 24 99 24 94 51 167 TP53 50%	RTK.RA	S PI3K 9 14 2 96 6 63 8 83 0 76 4 11 0 48 6 56 2 03 S PI3K % 43% % 39%	8% NRF2 3 5 3 5 3 2 3 2 5 4 5 2 3 1 5 2 3 4 5 2 5 4 5 2 5 4 5 2 5 4 5 2 5 4 5 2 5 4 5 2 5 4 5 1 5 2 5 1 5 1 5 1 5 1 5 1 5 1 5 1 5 1 5 1 5 1	NOTC	H N 23 27 1 27 1 27 1 29 1 29 1 29 1 29 1 24 1 29 1 27 1 29 1 29 1 27 1 29 1 29 1 29 1 29 1 29 1 29 1 29 1 29	AYC 48 21 33 36 32 37 45 24 47 22 47 22 147 22 147 22 147 22 147 22 247 17% 20%	HIPPC HIPPC HIPPC HIPPC HIPPC HIPPC 23 21 4	 Cell.C 3 2 6 9 4 3 2 4 3 2 5 0 <	Cycle 76 76 76 76 76 76 132 120 195 164 88 72 180 Cycle 64% 72%	Sample number 27 10 22 16 19 25 13 25 25 25 Sample number 27 25 25 25 25 25 25 25 25 25 25
D	Number FN1-noncna FN1-cna VCAN-cna HGF-noncna HGF-cna THBS1-noncna THBS1-cna FBN1-cna FBN1-cna MMP9-noncna MMP9-cna Percentage FN1-noncna FN1-cna VCAN-noncna	WNT TC 112 311 94 49 75 68 104 39 105 38 58 85 WNT TC 40% 42%	GF-Beta BF-Beta BF-Beta BF-Beta BF-Beta BF-Beta 31% 31% 31% 31% 31% 31% 31% 31%	TP53 139 94 24 83 15 19 99 24 94 51 167 TP53 50% 42%	RTK.RA 15 6 13 9 9 13 13 9 13 13 9 13 13 9 13 13 9 13 13 9 13 15 RTK.RA	S PI3K 9 14 9 14 9 14 9 14 9 14 12 96 6 63 8 83 0 76 4 11 4 44 8 11 0 48 11 0 48 6 56 2 03 8 PI3K 6 56 2 03 8 PI3K 8 21 11 0 48 6 39% 6 39% 6 39% 6 39% 6 39%	8% NRF2 3 5 5 3 5 4 5 3 2 5 4 1 5 2 3 1 5 3 1 5 3 1 5 3 1 5 3 1 1 5 2 3 4 5 2 7 6 2% 6 2% 6 1%	NOTC	H N 23 27 1 27 1 27 1 27 1 43 1 29 1 24 1 29 1 29 1 24 1 29 1 24 1 29 1 29 1 29 1 29 1 29 1 29 1 29 1 29	AYC 48 21 33 36 32 37 45 24 145 22 147 47 22 21 47 47 22 22 147 47 17% 20% 15%	HIPPC	 Cell.C Cell.C Cell.C Cell.C Cell.C 	Cycle 76 76 1 132 120 1133 157 95 164 88 72 180 20 20 20 20 20 20 20 20 20 20 20 20 20	Sample number 27 10 22 16 19 25 13 25 13 25 12 25 Sample number 27 10 23 25 25 25 25 25 25 25 25 25 25
D	Number FN1-noncna FN1-cna VCAN-noncna VCAN-cna HGF-cna THBS1-noncna FBN1-cna FBN1-cna MMP9-noncna MMP9-cna Percentage FN1-noncna FN1-cna VCAN-cna	WNT TC 12 31 94 49 75 68 104 39 105 38 58 85 WNT TC 40% 29% 42% 31%	GF-Beta 86 24 70 40 54 79 31 77 33 51 59 6F-Beta 31% 23% 31% 25%	TP53 139 94 124 83 135 199 99 124 94 511 167 TP53 50% 42% 42% 42% 42%	RTK.RA 15 6 13 9 9 13 13 9 13 13 9 13 13 9 13 13 9 13 13 9 13 15 15 15 15 15 15 15 15 15 15	S PI3K 9 118 9 141 2 96 6 6 63 8 83 0 76 4 111 4 48 111 4 48 4 111 4 48 4 111 0 48 6 56 2 0 03 S PI3K % 43% % 43% % 39%	8% NRF2 3 5 3 5 3 2 3 2 5 4 1 5 3 1 5 2 3 4 5 2 3 4 5 2 8 1 1 5 5 2 3 4 5 2 8 1 1 5 5 2 8 1 5	NOTC	H N 23 27 07 43 89 61 21 29 24 26 69 81 21 29 81 5% 81 81 5% 83% 7%	AYC 48 21 33 36 32 37 45 22 147 222 147 VYC 17% 20% 23%	HIPPC HI	 Cell.C Cell.C Cell.C Cell.C Cell.C Cell.C Cell.C Cell.C K K	cycle 76 76 76 76 1 132 120 133 157 95 164 88 72 180 Cycle 64% 59% 75%	Sample number 27 10 22 16 19 25 13 25 13 25 12 12 25 Sample number 27 25 13 12 12 12 12 12 12 13 12 13 12 13 12 13 13 14 15 15 15 15 15 15 15 15 15 15
D	Number FN1-noncna FN1-cna VCAN-noncna VCAN-cna HGF-noncna HGF-cna THBS1-noncna FBN1-noncna FBN1-cna MMP9-noncna MMP9-cna Percentage FN1-noncna FN1-cna VCAN-noncna VCAN-noncna VCAN-noncna	WNT TC 112 31 94 49 75 68 104 39 105 38 85 85 WNT TC 40% 29% 42% 39%	GF-Beta 244 70 40 56 54 79 31 77 33 51 59 6F-Beta 31% 23% 31% 25% 29%	TP53 139 94 24 83 135 199 99 24 94 51 167 TP53 50% 42% 42% 44%	RTK.RA 15 6 13 9 9 13 9 13 9 13 9 13 9 7 15 RTK.RA 57' 65' 59' 60'	S PI3K 9 14 2 96 6 63 8 83 0 76 4 11 4 4 48 8 11 0 48 6 56 2 03 S PI3K % 43% % 39% % 39% % 39%	8% NRF2 3 5 3 5 3 2 3 2 3 2 3 4 5 4 5 2 3 4 5 2 3 4 5 2 3 4 5 2 3 4 5 2 7 6 2% 6 2% 6 1% 7 6 2% 6 2%	NOTC	H N 23 27 07 43 89 61 29 61 29 61 24 26 69 81 24 5% 69 81 5% 5% 5% 5% 5%	MYC I 48 21 33 36 32 37 I 45 24 I 47 22 22 1 47 222 1 47 222 1 47 222 1 47 222 1 47 222 1 47 222 1 47 222 1 47 222 1 47 222 1 47 1 7% 20% 1 7% 23% 1 7% 1 7%	HIPPC 6 2 2 2 2 4 2 4 4 6 2 2 4 4 4 6 2 2 4 4 4 4 4 4 4 4 4 4 4 4 4 4	 Cell.C Cell.C G G<!--</td--><td>Cycle 76 76 76 132 120 132 120 133 157 95 164 88 72 180 Cycle 64% 72% 59% 59% 63%</td><td>Sample number 27 10 22 16 19 19 25 13 25 13 25 13 25 13 25 5 13 25 5 12 25 5 12 25 5 13 12 25 5 13 12 25 5 13 12 25 13 12 25 13 12 25 13 12 25 13 12 15 12 15 13 12 15 13 12 15 13 15 12 15 13 15 12 15 13 15 15 15 15 15 15 15 15 15 15</td>	Cycle 76 76 76 132 120 132 120 133 157 95 164 88 72 180 Cycle 64% 72% 59% 59% 63%	Sample number 27 10 22 16 19 19 25 13 25 13 25 13 25 13 25 5 13 25 5 12 25 5 12 25 5 13 12 25 5 13 12 25 5 13 12 25 13 12 25 13 12 25 13 12 25 13 12 15 12 15 13 12 15 13 12 15 13 15 12 15 13 15 12 15 13 15 15 15 15 15 15 15 15 15 15
D	Number FN1-noncna FN1-ona VCAN-ona HGF-ona HGF-ona HBS1-ona FBN1-noncna FBN1-noncna FBN1-ona MMP9-ona Percentage FN1-noncna FN1-ona VCAN-ona VCAN-ona HGF-onocna HGF-onocna	WNT TC 112 31 94 49 75 68 104 39 105 38 58 85 WNT TC 40% 22% 42% 31% 39% 35%	GF-Beta 36 36 37 37 37 37 37 37 37 37 37 37	TP53 139 79 94 24 83 15 199 24 94 51 167 TP53 50% 42% 42% 42% 44% 70% 44% 70% 44% 70% 10% 10% 10% 10% 10% 10% 10% 1	RTK.RA 15 6 13 9 9 13 13 9 13 13 9 13 13 9 13 13 9 13 13 9 13 13 9 13 13 9 13 13 9 13 13 9 13 13 9 13 13 13 9 13 13 13 9 13 13 13 13 13 13 13 13 13 13	S PI3K 9 14 9 14 9 14 9 14 9 14 6 6 6 63 8 8 8 30 7 6 4 11 0 48 6 56 2 03 8 11 0 48 6 56 2 03 8 PI3K 8 43% % 39% % 43% % 39%	8% NRF2 3 5 5 3 3 2 5 4 5 3 5 4 5 2 5 4 5 2 5 4 5 2 5 4 5 2 7 6 1% 6 1% 6 1% 6 1% 6 1% 6 1% 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	NOTC	H N 23 27 07 43 29 61 29 61 29 24 26 81 29 81 24 5% 69 81 5% 87% 7%	MYC 48 21 33 36 32 37 45 24 47 22 22 1 47 MYC 17% 23% 17% 10% 17%	HIPPC HI	0 Cell.C 3 2 6 3 9 3 3 2 5 3 0 3 5 3 0 3 5 3 0 3 5 3 0 3 <td< td=""><td>Eycle 176 76 1132 120 119 133 157 95 164 88 72 180 Eycle 64% 72% 59% 75% 63% 64%</td><td>Sample number 27 10 22 16 19 25 13 25 13 25 5 25 5 25 5 5 25 5 5 25 5 5 25 5 5 25 5 5 25 5 25 5 25 5 25 5 25 5 25 2</td></td<>	Eycle 176 76 1132 120 119 133 157 95 164 88 72 180 Eycle 64% 72% 59% 75% 63% 64%	Sample number 27 10 22 16 19 25 13 25 13 25 5 25 5 25 5 5 25 5 5 25 5 5 25 5 5 25 5 5 25 5 25 5 25 5 25 5 25 5 25 2
D	Number FN1-noncna FN1-cna VCAN-cna HGF-noncna HGF-cna THBS1-cna FBN1-noncna FBN1-cna MMP9-noncna MMP9-noncna MMP9-cna Percentage FN1-noncna FN1-cna	WNT TC 112 31 94 49 75 68 104 39 105 38 58 85 WNT TC 40% 29% 42% 31% 39% 35%	GF-Beta 36 36 37 31 37 33 51 59 31% 31% 25% 29% 28% 20% 28% 20% 28% 20% 20% 20% 20% 20% 20% 20% 20	TP53 139 94 24 83 35 19 99 24 94 94 94 51 167 TP53 50% 42% 44% 44% 94% 94% 197 197 197 197 197 197 197 197	RTK.RA 15 6 6 13 9 9 9 13 13 9 9 13 13 9 9 13 13 9 9 7 15 RTK.RA 57 ⁴ 55 ⁹ 60 ⁶ 52 ⁹ 60 ⁶	S PI3K 9 1 18 9 1 41 9 1 41 2 96 6 6 63 8 8 83 0 76 4 11 4 4 4 8 11 4 4 48 6 56 2 0 3 8 8 11 4 4 48 6 56 2 0 3 8 8 11 6 56 2 0 3 8 8 3 8 3 9 3 8 43 % 39% % 44%	8% NRF2 3 5 3 5 3 2 5 4 1 5 3 2 5 4 1 5 3 1 5 2 3 4 5 2% 6 1% 6 1% 6 1% 6 1% 6 1% 6 1%	NOTC	H N 23 27 07 43 61 29 24 26 61 29 24 26 69 81 29 81 5% 81 5% 5% 7% 7% 7% 2% 2% 2% 2% 2% 2% 2% 2% 2% 2	MYC 1 48 21 33 36 32 37 1 45 24 1 47 22 1 47 22 1 47 22 1 47 17% 20% 15% 15% 15% 19% 00% 19% 00% 19% 19% 19% 19% 19% 19% 19% 19	HIPPC HIPPC HIPPC HIPPC HIPPC HIPPC 18" 23" 21" 23" 21" 21" 21" 21" 21" 21" 21" 21	 Cell.C Cell.C Cell.C Cell.C Cell.C Cell.C Cell.C K 	Sycle 76 76 76 76 1 132 120 119 1 133 157 95 1164 88 72 180 7164 88 72 180 64% 72% 63% 63%	Sample number 27 10 22 16 19 25 13 25 13 25 13 25 12 12 12 25 Sample number 27 10 23 10 19 25 13 25 13 25 13 25 13 25 10 19 25 10 25 10 19 25 10 19 25 10 19 25 10 19 25 10 19 25 10 19 25 10 19 25 10 19 25 10 19 25 10 19 25 10 19 25 10 19 25 10 19 25 10 19 25 10 19 25 10 10 19 25 10 10 10 10 10 10 10 10 10 10
D	Number FN1-noncna FN1-cna VCAN-noncna VCAN-cna HGF-ona THBS1-noncna FBN1-cna FBN1-cna MMP9-noncna FBN1-cna MMP9-cna Percentage FN1-noncna FN1-cna VCAN-noncna VCAN-noncna VCAN-cna HGF-oncna HGF-cna THBS1-noncna	WNT TC 112 31 94 49 75 68 104 39 105 38 104 39 105 38 85 WNT TC 40% 29% 42% 31% 39% 35% 42%	GF-Beta 264 270 40 56 54 799 311 77 33 51 59 6F-Beta 31% 23% 31% 25% 28% 32%	TP53 139 79 94 24 83 135 199 99 24 94 51 167 TP53 50% 42% 42% 42% 478% 44% 48%	RTK.RA 15 6 13 9 9 13 9 13 9 13 9 13 9 13 9 13 13 9 9 13 13 9 9 13 13 9 9 13 13 9 9 13 15 15 15 15 15 15 15 15 15 15	S PI3K 9 141 2 96 6 63 8 83 0 76 4 11 4 4 48 8 111 0 48 6 56 2 03 S PI3K % 43% % 39% % 44% % 39% % 44%	8% NRF2 3 5 3 5 3 2 3 2 3 2 3 2 3 4 4 5 2 3 4 5 4 5 2 7 6 2% 6 2% 6 2% 6 2% 6 2%	NOTC NOTC 1 1 1 1 1 1 1 1 1 1 1 1 1	H N 23 27 07 43 89 61 21 24 26 69 81 24 26 81 24 26 81 5% 88 7% 7% 7% 2%	MYC I 48 21 33 36 32 37 I 45 24 I 47 22 22 1 47 22 22 1 47 22 1 47 22 22 1 47 15% 23% 15% 19% 18% 19% 18% 19% 18% 18% 18% 18% 18% 18% 18% 18	HIPPC 6 2 2 2 2 4 2 4 4 6 2 2 4 4 6 2 2 4 4 4 6 2 2 4 4 4 6 4 4 4 6 4 4 4 4 4 4 4 4	0 Cell.C 3 2 6 9 1 1 3 2 5 0 0 0 5 0 0 0 <td< td=""><td>ycle 176 76 132 120 132 157 95 164 88 72 180 59% 59% 63% 63% 63%</td><td>Sample number 27 10 22 16 19 25 13 25 13 25 12 12 25 Sample number 27 5 10 19 19 25 13 12 12 12 12 13 12 13 12 13 12 13 13 14 19 19 19 19 19 19 19 19 19 19</td></td<>	ycle 176 76 132 120 132 157 95 164 88 72 180 59% 59% 63% 63% 63%	Sample number 27 10 22 16 19 25 13 25 13 25 12 12 25 Sample number 27 5 10 19 19 25 13 12 12 12 12 13 12 13 12 13 12 13 13 14 19 19 19 19 19 19 19 19 19 19
D	Number FN1-noncna FN1-cna VCAN-cna HGF-cna HGF-cna THBS1-noncna FBN1-noncna FBN1-noncna FBN1-cna MMP9-noncna MMP9-cna Percentage FN1-noncna FN1-cna VCAN-noncna VCAN-noncna HGF-noncna HGF-noncna THBS1-noncna THBS1-noncna	WNT TC 112 31 94 49 75 68 104 39 105 38 58 85 WNT TC 40% 29% 42% 39% 35% 42% 29%	GF-Beta	TP53 139 79 94 24 83 355 199 99 24 94 51 167 TP53 50% 42% 42% 44% 48% 48% 48% 48% 48% 48% 48	RTK.RA 15 6 13 9 9 13 13 9 13 9 13 9 13 9 13 9 13 9 13 13 9 13 13 9 13 13 9 13 13 9 13 13 9 13 13 9 13 13 13 13 13 13 13 13 13 13	S PI3K 9 1 18 9 1 41 2 96 6 6 38 8 83 0 76 4 11 2 96 6 6 36 76 4 11 4 4 4 8 11 0 4 4 8 39% % 43% % 39% % 44% % 39% % 44% % 39%	8% NRF2 3 5 5 3 5 4 5 4 5 4 5 4 5 4 5 4 5 4 5 4 5 4 5 4	NOTC NOTC 1 1 1 1 1 1 1 1 1 1 1 1 1	H N 23 27 07 43 89 61 21 29 24 26 29 24 26 81 29 81 29 81 81 81 83 83 83 7% 7% 7% 2% 83% 2%	MYC 48 21 33 36 32 37 45 24 45 24 1 47 22 22 1 47 22 21 47 15% 23% 15% 17% 15% 13% 18%	HIPPC 6 2 2 6 2 6 2 6 2 6 2 6 2 6 2 6	0 Cell.C 3 2 6 9 9 3 2 3 3 2 5 0 0 0 5 0 0 0 <td< td=""><td>ycle 76 76 76 76 132 120 119 133 157 95 164 88 872 180 59% 72% 63% 63% 63% 63% 71%</td><td>Sample number 27 10 22 10 22 10 22 10 19 25 13 25 13 25 25 25 25 25 25 25 25 25 25</td></td<>	ycle 76 76 76 76 132 120 119 133 157 95 164 88 872 180 59% 72% 63% 63% 63% 63% 71%	Sample number 27 10 22 10 22 10 22 10 19 25 13 25 13 25 25 25 25 25 25 25 25 25 25
D	Number FN1-noncna FN1-ona VCAN-ona HGF-ona HGF-ona THBS1-ona FBN1-oncna FBN1-oncna FBN1-oncna MMP9-oncna MMP9-oncna Percentage FN1-noncna FN1-ona VCAN-oncna VCAN-oncna HGF-ona HGF-ona THBS1-ona FBN1-noncna FBN1-noncna	WNT TC 112 31 94 49 75 68 104 39 105 38 58 85 WNT TC 40% 29% 42% 31% 39% 35% 42% 42% 41%	GF-Beta 36 36 37 37 37 37 37 37 37 37 37 37	TP53 139 799 94 24 83 159 99 24 94 51 167 TP53 50% 42% 44% 44% 44% 48%	RTK.RA 15 6 13 9 9 9 13 13 9 13 13 9 7 15 RTK.RA 52' 59' 60' 52' 59' 50' 50' 50' 50' 50' 50' 50' 50	 Y/% S PI3K 9 16 9 412 96 6 63 8 830 76 4 <l< td=""><td>8% NRF2 3 5 5 3 3 2 5 4 5 3 3 2 5 4 5 2 8 1 5 2 8 1 5 2 8 1 5 2 8 1 5 2 8 1 5 2 8 1 5 2 8 1 7 5 5 2 8 1 7 5 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7</td><td>NOTC NOTC NOTC</td><td>H N 23 27 27 43 89 61 29 24 26 69 81 29 24 60 81 29 81 5% 88% 7% 7% 7% 7% 88% 2%</td><td>AYC 48 21 33 36 32 37 45 24 47 22 22 1 47 47 22 22 1 47 47 23% 15% 23% 19% 18% 18%</td><td>HIPPC HIPCC HIPCC HIPCC HIPCC HI</td><td>0 Cell.C 3 2 6 9 9 4 1 3 2 5 0 0 5 0 0 0 5 0 0 0 0 0 5 0 0 0 5 0 0 0 0 0 5 0 0 0 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 <</td><td>Eycle 176 761 1322 1202 1333 157 955 164 88 72 180 595 63% 63% 63% 63% 64%</td><td>Sample number 27 10 22 10 22 10 19 25 13 25 12 12 12 12 12 12 12 12 12 12</td></l<>	8% NRF2 3 5 5 3 3 2 5 4 5 3 3 2 5 4 5 2 8 1 5 2 8 1 5 2 8 1 5 2 8 1 5 2 8 1 5 2 8 1 5 2 8 1 7 5 5 2 8 1 7 5 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	NOTC NOTC NOTC	H N 23 27 27 43 89 61 29 24 26 69 81 29 24 60 81 29 81 5% 88% 7% 7% 7% 7% 88% 2%	AYC 48 21 33 36 32 37 45 24 47 22 22 1 47 47 22 22 1 47 47 23% 15% 23% 19% 18% 18%	HIPPC HIPCC HIPCC HIPCC HIPCC HI	0 Cell.C 3 2 6 9 9 4 1 3 2 5 0 0 5 0 0 0 5 0 0 0 0 0 5 0 0 0 5 0 0 0 0 0 5 0 0 0 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 <	Eycle 176 761 1322 1202 1333 157 955 164 88 72 180 595 63% 63% 63% 63% 64%	Sample number 27 10 22 10 22 10 19 25 13 25 12 12 12 12 12 12 12 12 12 12
D	Number FN1-noncna FN1-cna VCAN-noncna VCAN-cna HGF-noncna HGS1-noncna FBN1-cna FBN1-cna MMP9-noncna FBN1-cna MMP9-cna Percentage FN1-noncna FN1-cna VCAN-noncna VCAN-noncna HGF-noncna HGF-noncna HGF1-cna THBS1-noncna FBN1-cna	WNT TC 112 31 94 49 75 68 104 39 105 38 58 85 WNT TC 40% 29% 42% 39% 35% 42% 29% 41% 30%	GF-Beta 36 36 36 36 37 30 37 37 33 51 59 37 31% 25% 23% 31% 25% 22% 22% 32% 32% 32% 32% 26%	TP53 139 79 94 124 83 135 199 99 124 94 51 167 TP53 50% 42% 48% 48% 48% 48% 48% 57% 44% 57% 50% 44% 57% 50% 50% 50% 50% 50% 50% 50% 50	RTK.RA 15 6 13 9 9 13 9 9 13 9 9 13 9 9 13 13 9 9 13 13 9 9 13 13 9 9 13 13 9 9 13 13 9 9 13 13 9 9 13 13 9 9 13 13 13 9 9 13 13 13 9 9 13 13 13 13 13 13 13 13 13 13	S PI3K 9 141 2 96 6 63 8 83 0 41 14 4 148 8 111 0 48 6 56 2 03 S PI3K % 43% % 39% % 44% % 39% % 44% % 39% % 44% % 39% % 44% % 39% % 44% % 39% % 38%	8% NRF2 3 5 5 3 3 2 5 4 5 3 3 2 5 4 1 5 5 2 3 4 5 4 5 2 7 6 2 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	NOTC NOTC 1 1 1 1 1 1 1 1 1 1 1 1 1	H N 23 27 27 43 89 61 21 29 24 26 69 24 26 69 81 29 24 81 69 81 81 69 81 81 69 81 81 7% 7% 7% 2% 8% 8% 7%	MYC 48 21 33 36 32 37 45 24 145 22 22 147 22 22 147 47 22 22 147 15% 15% 15% 15% 15% 15% 15% 15%	HIPPC 4 4 4 4 4 4 4 4 4 4 4 4 4	0 Cell.C 3 2 6 3 9 1 1 1 3 2 5 1 0 2 5 1 0 2 <	 cycle 76 76 76 76 76 132 157 95 164 80 22 180 59% 63% 63% 63% 64% 70% 	Sample number 27 10 22 10 22 10 19 19 25 13 25 5 5 5 5 5 5 5 5 5 5 5 5 5
D	Number FN1-noncna FN1-cna VCAN-cna HGF-cna THBS1-noncna THBS1-noncna FBN1-noncna FBN1-cna MMP9-noncna MMP9-cna Percentage FN1-noncna FN1-cna VCAN-noncna VCAN-noncna HGF-noncna HGF-cna THBS1-noncna FBN1-noncna FBN1-noncna FBN1-noncna FBN1-noncna FBN1-noncna FBN1-noncna FBN1-noncna	WNT TC 112 31 94 49 75 68 104 39 105 38 58 85 WNT TC 40% 42% 42% 42% 42% 42% 42% 42% 42	69% 6F-Beta 86 244 700 40 56 54 799 311 77 33 51 59 6F-Beta 31% 23% 31% 25% 28% 32% 28% 32% 28% 30% 28% 40% 40% 40% 40% 40% 40% 40% 40	TP53 139 94 24 83 135 199 94 24 94 51 167 TP53 50% 42% 44% 44% 44% 44% 48% 44% 48% 44% 48% 48	RTK.RA 15 6 13 9 9 13 9 13 9 13 9 13 9 13 9 13 13 9 9 13 13 9 9 13 13 9 9 13 13 9 9 13 13 9 9 13 15 59 60 60 59 60 60 59 60 60 59 60 60 59 60 60 59 60 60 59 60 60 59 60 60 59 60 60 59 60 60 59 60 60 59 60 60 59 60 60 59 60 60 59 60 60 59 60 60 59 59 60 60 59 59 60 59 59 60 59 59 60 59 59 59 59 59 59 59 59 59 59	 Y/% S PI3K 9 18 9 412 96 6 63 8 830 76 4 <l< td=""><td>8% NRF2 3 5 5 3 3 2 5 4 5 4 5 2 3 4 5 4 5 2 5 4 5 2 5 4 5 2 7 6 2% 6 2% 6 2% 6 2% 6 2% 6 2% 6 2% 6 2%</td><td>NOTC NOTC 1 1 1 1 1 1 1 1 1 1 1 1 1</td><td>H N 227 07 43 27 43 27 43 27 43 20 24 26 50 69 24 26 50 69 24 24 26 81 24 26 81 27 50 81 81 70 70 70 70 83 70 70 83 83 83 83 83 83 83 83 83 83 84 84 84 84 84 84 84 84 84 84 84 84 84</td><td>MYC 48 21 33 36 32 37 45 24 145 22 22 147 22 22 147 22 21 47 23% 15% 23% 15% 15% 18% 18% 18% 18%</td><td>HIPPC 6 2 2 2 2 4 2 4 4 6 2 2 4 4 6 2 2 4 4 4 6 2 2 4 4 4 6 2 2 4 4 4 7 2 3 2 1 2 3 2 1 2 3 2 1 2 3 2 1 2 3 2 1 2 3 2 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4</td><td>0 Cell.C 3 - 6 - 9 - 1 - 3 - 5 - 0 - 5 - 0 - <td< td=""><td>yycle 176 76 76 132 122 120 119 133 157 95 164 88 72 180 2 180 2 4% 72% 63% 63% 63% 71% 64% 70% 56%</td><td>Sample number 27 10 22 16 19 19 25 13 25 5 12 25 5 13 25 5 13 25 5 12 25 5 13 25 5 12 25 5 13 25 5 12 25 5 13 25 5 13 25 5 13 25 5 13 25 5 12 25 5 13 25 5 12 25 5 13 12 25 5 13 12 25 5 12 25 5 12 25 5 12 25 5 12 25 5 12 25 5 12 25 5 12 25 5 12 25 5 12 25 5 13 15 15 15 15 15 15 15 15 15 15</td></td<></td></l<>	8% NRF2 3 5 5 3 3 2 5 4 5 4 5 2 3 4 5 4 5 2 5 4 5 2 5 4 5 2 7 6 2% 6 2% 6 2% 6 2% 6 2% 6 2% 6 2% 6 2%	NOTC NOTC 1 1 1 1 1 1 1 1 1 1 1 1 1	H N 227 07 43 27 43 27 43 27 43 20 24 26 50 69 24 26 50 69 24 24 26 81 24 26 81 27 50 81 81 70 70 70 70 83 70 70 83 83 83 83 83 83 83 83 83 83 84 84 84 84 84 84 84 84 84 84 84 84 84	MYC 48 21 33 36 32 37 45 24 145 22 22 147 22 22 147 22 21 47 23% 15% 23% 15% 15% 18% 18% 18% 18%	HIPPC 6 2 2 2 2 4 2 4 4 6 2 2 4 4 6 2 2 4 4 4 6 2 2 4 4 4 6 2 2 4 4 4 7 2 3 2 1 2 3 2 1 2 3 2 1 2 3 2 1 2 3 2 1 2 3 2 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	0 Cell.C 3 - 6 - 9 - 1 - 3 - 5 - 0 - 5 - 0 - <td< td=""><td>yycle 176 76 76 132 122 120 119 133 157 95 164 88 72 180 2 180 2 4% 72% 63% 63% 63% 71% 64% 70% 56%</td><td>Sample number 27 10 22 16 19 19 25 13 25 5 12 25 5 13 25 5 13 25 5 12 25 5 13 25 5 12 25 5 13 25 5 12 25 5 13 25 5 13 25 5 13 25 5 13 25 5 12 25 5 13 25 5 12 25 5 13 12 25 5 13 12 25 5 12 25 5 12 25 5 12 25 5 12 25 5 12 25 5 12 25 5 12 25 5 12 25 5 12 25 5 13 15 15 15 15 15 15 15 15 15 15</td></td<>	yycle 176 76 76 132 122 120 119 133 157 95 164 88 72 180 2 180 2 4% 72% 63% 63% 63% 71% 64% 70% 56%	Sample number 27 10 22 16 19 19 25 13 25 5 12 25 5 13 25 5 13 25 5 12 25 5 13 25 5 12 25 5 13 25 5 12 25 5 13 25 5 13 25 5 13 25 5 13 25 5 12 25 5 13 25 5 12 25 5 13 12 25 5 13 12 25 5 12 25 5 12 25 5 12 25 5 12 25 5 12 25 5 12 25 5 12 25 5 12 25 5 12 25 5 13 15 15 15 15 15 15 15 15 15 15
D	Number FN1-noncna FN1-cna VCAN-cna HGF-noncna HGF-cna THBS1-ona FBN1-noncna FBN1-noncna FBN1-cna MMP9-noncna MMP9-cna Percentage FN1-noncna FN1-cna VCAN-noncna HGF-cna THBS1-cna HGF-cna THBS1-cna FBN1-noncna FBN1-noncna FBN1-cna MMP9-cna	WNT TC 112 31 94 49 75 68 104 39 105 38 58 85 WNT TC 40% 29% 42% 39% 39% 35% 42% 29% 41% 30% 45% 33%	GF-Beta 36 36 37 37 37 37 37 37 37 37 37 37	TP53 139 79 94 124 83 15 199 99 124 99 124 51 167 TP53 50% 42% 48% 48% 48% 48% 48% 48% 48% 48	RTK.RA 15 6 13 9 9 13 13 9 13 9 13 13 13 9 13 13 9 13 13 9 13 13 9 13 13 13 9 15 15 15 15 15 15 15 15 15 15	S PI3K 9 14 9 41 2 96 6 6 63 8 8 83 0 76 4 11 0 48 6 56 2 0 3 8 11 0 48 6 56 2 0 3 8 91 8 43% 6 39% 6 43% 6 39% 6 43% 6 39% 6 43% 6 39% 6 43% 6 39% 6 43% 6 39% 6 44% 6 38% 6 44% 6	8% NRF2 3 5 5 3 3 2 5 4 5 3 5 4 5 4 5 2 5 4 5 4 5 2 5 4 5 4 5 2 5 4 5 1 5 2 5 4 6 1% 6 1% 6 2% 6 1% 6 2% 6 1% 6 2% 6 1% 6 1% 6 2%	NOTCC NOTCC 1 1 1 1 1 1 1 1 1 1 1 1 1	H N 23 27 1 27 1 07 1 43 2 61 2 29 1 29 1 29 1 29 1 29 1 29 1 29 1 2	AYC 48 21 33 36 32 37 45 24 47 22 22 1 47 22 21 47 22 21 47 23% 17% 23% 17% 15% 23% 17% 18% 18% 18% 18%	HIPPC HI	0 Cell.C 3 2 6 3 9 3 3 2 5 0 0 0 5 0 0 0 5 0 0 0 0	cycle 176 76 132 120 119 120 195 164 88 72 164 88 72 164 88 72 164 88 72 164 88 72 164 88 72 164 88 72 164 87 75% 63% 63% 63% 63% 71% 63% 71% 63% 71% 63% 71% 63% 71% 71% 71% 71% 75% 75% 63% 71% 71% 71% 75% 75% 63% 71% 71% 75% 75% 75% 75% 75% 75% 75% 75	Sample number 27 10 22 10 22 10 19 25 13 25 25 25 25 25 25 25 25 25 25

target genes, (**B**) percentage of change numbers in each pathway for the mutated and wild type groups of target genes, (**C**) number of changes in each pathway for the CNA and non-CNA groups of target genes, (**D**) percentage of change numbers in each pathway for the CNA and non-CNA groups of target genes. ***P < 0.005; **P < 0.01; *P < 0.05.

and oncogenic signaling pathways, we expect that the six genes could be considered as new prognostic targets in GC.

In terms of mRNA, a high negative correlation was found between the target genes and purity and TME score. Studies have shown that as purity decreases, it becomes more challenging for drugs to penetrated into the tumor, leading to a lower recognition and elimination ratio by endogenous immune cells (Mao et al., 2018; Rhee et al., 2018). The TME score is an approach to estimate the microenvironment surrounding the tumor cells. Studies have found that higher TME scores show improved immune treatment and prognosis (Junttila and de Sauvage, 2013; Lazar et al., 2018; Zeng et al., 2019). In our study, all six genes, except *MMP9*, showed a significant negative correlation with tumor purity and TME score. Additionally, improved survival was observed in lower mRNA expression groups. Meanwhile, low mRNA expression of *FBN1*, *THBS1*, and *VCAN* was observed



in earlier stages, and lower expression of all six genes, except *MMP9*, was observed in earlier grades. Taken together, this indicates that the lower expression of these target genes may play a role in improving tumor purity and TME to display a better prognosis of GC.

Regarding somatic mutation, significantly higher TMBs and TME scores were observed in groups with mutations in the target genes. TMB was calculated based on the number of mutations per gene. Patients with higher TMB have been found to have a better prognosis (Hellmann et al., 2018; Maleki Vareki, 2018; Wang F. et al., 2019; Kim et al., 2020). As the tumor reaches a higher TMB, it is more likely to have more neoantigens that could be recognized and killed by endogenous immune cells. Additionally, TME scores have been shown to have a positive correlation with TMB (Zeng et al., 2019). In our study, the mutation frequency of the target genes is shown in Figure 6. When the six genes have mutations, their mRNA expression level is not affected, but the TMB increased in all mutated groups. Additionally, higher TME scores were observed in all target genes except HGF. No significant difference was found for tumor purity, immune score, or stromal score. In addition, THBS1 mutations were associated with an earlier stage while the VCAN mutations were associated with a lower grade. Taken together, these results indicate that the mutation of these target genes may affect the clinical stage and

grade, and improve the prognosis or treatment by affecting the TMB and TME score.

CNA primarily affects tumor purity. Five CNA types, including homozygous deletion, single copy deletion, normal copy, low amplification, and high amplification, were observed, with single copy deletion and low amplification being the most common. CNA of each target gene reflected higher tumor purity and lower immune and stromal scores. No significant difference was observed in TMB or TME score. In addition, the CNA of four target genes (*FBN1*, *HGF*, *THBS1*, and *VCAN*) led to lower mRNA expression of the gene compared to a normal group. Lower expression of target genes was associated with better prognosis, as shown in **Figure 9**. Therefore, we believe that the CNA of target genes may significantly reduce their mRNA expression and improve the purity of the tumor to affect the prognosis of GC.

To explore the possible pathways affected by the six target genes, we investigated the relationship between the target genes and 10 classic oncogenic signaling pathways that have been proven to play important roles in the occurrence and development of cancer (Joshi-Tope et al., 2005; Ciriello et al., 2013; Bahceci et al., 2017; Sanchez-Vega et al., 2018). The cooccurrence and mutual exclusivity between the key genes of each pathway and our target genes were calculated (Tyner et al., 2018).

Frontiers in Genetics | www.frontiersin.org

The target genes are related to multiple pathways. Mutations of the target genes can be accompanied by alterations in multiple pathways, including mutations, methylation, CNA, etc. In addition, the target genes tended to co-occur with key genes in the NOTCH and HIPPO pathways. Some genes that targets co-occurred with, such as *BRAF*, *PDGFRB*, *APC*, *IGF1R*, and *MTOR*, have been targeted by drugs to treat tumor progression (Wang et al., 2014; Kavuri et al., 2015; Long et al., 2015; Smyth et al., 2016; David et al., 2017; Zhang et al., 2018; Sullivan et al., 2019). In the clinical treatment of patients with alterations in the target genes, we can choose to study the classic pathway where these relevant pleiotropic genes are located to then apply relevant drugs for clinical treatment. This will further clarify our research and therapeutic directions, and enhance treatment.

In summary, *FBN1*, *FN1*, *HGF*, *MMP9*, *THBS1*, and *VCAN* can be used as new target genes to observe the prognosis of gastric cancer. The lower the expression, the better the prognosis. The mutation of target genes may affect the TMB and TME score of the tumor, while their CNA may make an impact on the purity of the tumor. By exploring the relationship between target genes and hub genes in oncogenic signaling pathways that they co-occur with, such as *BRAF*, *PIK3CA*, *APC*, *MTOR*, etc., that have been proven in targeted therapy, we can choose more suitably potential research mechanisms to improve the prognosis of GC. We will further collect clinical samples and study the mechanisms in detail through *in vitro* and *in vivo* experiments.

DATA AVAILABILITY STATEMENT

Publicly available datasets were analyzed in this study. This data can be found here: https://portals.broadinstitute.org/ccle; https:

REFERENCES

- Appleby, T. C., Greenstein, A. E., Hung, M., Liclican, A., Velasquez, M., Villasenor, A. G., et al. (2017). Biochemical characterization and structure determination of a potent, selective antibody inhibitor of human MMP9. *J. Biol. Chem.* 292, 6810–6820. doi: 10.1074/jbc.M116.760579
- Aran, D., Sirota, M., and Butte, A. J. (2015). Systematic pan-cancer analysis of tumour purity. *Nat. Commun.* 6:8971.
- Bahceci, I., Dogrusoz, U., La, K. C., Babur, O., Gao, J., and Schultz, N. (2017). PathwayMapper: a collaborative visual web editor for cancer pathways and genomic data. *Bioinformatics* 33, 2238–2240. doi: 10.1093/bioinformatics/ btx149
- Bernini, M., and Bencini, L. (2012). Multimodal treatment of gastric cancer: surgery, chemotherapy, radiotherapy, and timing. *Int. J. Surg. Oncol.* 2012:246290. doi: 10.1155/2012/246290
- Chen, B., Khodadoust, M. S., Liu, C. L., Newman, A. M., and Alizadeh, A. A. (2018). "Profiling Tumor Infiltrating Immune Cells with CIBERSORT," in *Cancer Systems Biology: Methods and Protocols*, ed. L. von Stechow (New York, NY: Springer), 243–259.
- Chin, C. H., Chen, S. H., Wu, H. H., Ho, C. W., Ko, M. T., and Lin, C. Y. (2014). cytoHubba: identifying hub objects and sub-networks from complex interactome. *BMC Syst. Biol.* 8(Suppl. 4):S11. doi: 10.1186/1752-0509-8-S4-S11
- Ciriello, G., Miller, M. L., Aksoy, B. A., Senbabaoglu, Y., Schultz, N., and Sander, C. (2013). Emerging landscape of oncogenic signatures across human cancers. *Nat. Genet.* 45, 1127–1133. doi: 10.1038/ng.2762
- Cui, Y., Li, Q., Li, H., Wang, Y., Wang, H., Chen, W., et al. (2017). Asparaginyl endopeptidase improves the resistance of microtubule-targeting drugs in gastric

//www.cancerrxgene.org/; https://www.cancer.gov/; https://xena.ucsc.edu/.

AUTHOR CONTRIBUTIONS

YL and L-PL were the guarantors and designed the study. YL, J-SW, and H-CW participated in the acquisition, analysis, and interpretation of the data, and drafted the initial manuscript. TZ participated in the statistics analysis. J-SW and L-PL completed the review and editing. All authors contributed to the article and approved the submitted version.

FUNDING

The article was supported by the Key Technology Research and Development Program of Shandong (Grant Nos. 2017GSF221018 and 2017G006007).

ACKNOWLEDGMENTS

We thank all authors for agreeing to share their data.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fgene. 2020.00865/full#supplementary-material

cancer through IQGAP1 modulating the EGFR/JNK/ERK signaling pathway. *Onco Targets Ther.* 10, 627–643. doi: 10.2147/OTT.S125579

- Cutcutache, I., Wu, A. Y., Suzuki, Y., McPherson, J. R., Lei, Z., Deng, N., et al. (2016). Abundant copy-number loss of CYCLOPS and STOP genes in gastric adenocarcinoma. *Gastric Cancer* 19, 453–465. doi: 10.1007/s10120-015-0514-z
- David, P., Smi, E. F., Harry, J. M. G., Julien, M., Besse, B., Åslaug, H., et al. (2017). Dabrafenib plus trametinib in patients with previously untreated BRAFV600Emutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. *Lancet Oncol.* 18, 1307–1316. doi: 10.1016/s1470-2045(17)30679-4
- Ding, X., Xi, W., Ji, J., Cai, Q., Jiang, J., Shi, M., et al. (2018). HGF derived from cancerassociated fibroblasts promotes vascularization in gastric cancer via PI3K/AKT and ERK1/2 signaling. *Oncol. Rep.* 40, 1185–1195. doi: 10.3892/or. 2018.6500
- Duarte, H. O., Freitas, D., Gomes, C., Gomes, J., Magalhaes, A., and Reis, C. A. (2016). Mucin-Type O-glycosylation in gastric carcinogenesis. *Biomolecules* 6:33. doi: 10.3390/biom6030033
- Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., et al. (2015). Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int. J. Cancer* 136, E359–E386. doi: 10.1002/ijc. 29210
- Geng, B., Pan, J., Zhao, T., Ji, J., Zhang, C., Che, Y., et al. (2018). Chitinase 3like 1-CD44 interaction promotes metastasis and epithelial-to-mesenchymal transition through beta-catenin/Erk/Akt signaling in gastric cancer. J. Exp. Clin. Cancer Res. 37:208. doi: 10.1186/s13046-018-0876-2
- Hellmann, M. D., Callahan, M. K., Awad, M. M., Calvo, E., Ascierto, P. A., Atmaca, A., et al. (2018). Tumor mutational burden and efficacy of nivolumab

monotherapy and in combination with ipilimumab in small-cell lung cancer. Cancer Cell 33, 853,e4-861.e4.

- Huang, Y. K., Wang, M., Sun, Y., Di Costanzo, N., Mitchell, C., Achuthan, A., et al. (2019). Macrophage spatial heterogeneity in gastric cancer defined by multiplex immunohistochemistry. *Nat. Commun.* 10:3928. doi: 10.1038/ s41467-019-11788-4
- Jiang, K., Liu, H., Xie, D., and Xiao, Q. (2019). Differentially expressed genes ASPN, COL1A1, FN1, VCAN and MUC5AC are potential prognostic biomarkers for gastric cancer. *Oncol. Lett.* 17, 3191–3202. doi: 10.3892/ol.2019. 9952
- Joshi-Tope, G., Gillespie, M., Vastrik, I., D'Eustachio, P., Schmidt, E., de Bono, B., et al. (2005). Reactome: a knowledgebase of biological pathways. *Nucleic Acids Res.* 33, D428–D432. doi: 10.1093/nar/gki072
- Junttila, M. R., and de Sauvage, F. J. (2013). Influence of tumour microenvironment heterogeneity on therapeutic response. *Nature* 501, 346–354. doi: 10.1038/nature12626
- Kamangar, F., Dores, G. M., and Anderson, W. F. (2006). Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. *J. Clin. Oncol.* 24, 2137–2150. doi: 10.1200/JCO.2005.05.2308
- Kavuri, S. M., Jain, N., Galimi, F., Cottino, F., Leto, S. M., Migliardi, G., et al. (2015). HER2 activating mutations are targets for colorectal cancer treatment. *Cancer Discov.* 5, 832–841. doi: 10.1158/2159-8290.CD-14-1211
- Kim, J., Kim, B., Kang, S. Y., Heo, Y. J., Park, S. H., Kim, S. T., et al. (2020). Tumor mutational burden determined by panel sequencing predicts survival after immunotherapy in patients with advanced gastric cancer. *Front. Oncol.* 10:314. doi: 10.3389/fonc.2020.00314
- Kunkler, I. (1994). Cancer of the upper gastrointestinal tract. Palliative chemotherapy unproved in advanced gastric cancer. *BMJ* 308, 1508–1509. doi: 10.1136/bmj.308.6942.1508b
- Lazar, D. C., Avram, M. F., Romosan, I., Cornianu, M., Taban, S., and Goldis, A. (2018). Prognostic significance of tumor immune microenvironment and immunotherapy: novel insights and future perspectives in gastric cancer. World J. Gastroenterol. 24, 3583–3616. doi: 10.3748/wjg.v24.i32. 3583
- Lee, J. C., Su, S. Y., Changou, C. A., Yang, R. S., Tsai, K. S., Collins, M. T., et al. (2016). Characterization of FN1-FGFR1 and novel FN1-FGF1 fusion genes in a large series of phosphaturic mesenchymal tumors. *Mod. Pathol.* 29, 1335–1346. doi: 10.1038/modpathol.2016.137
- Li, M., Spakowicz, D., Burkart, J., Patel, S., Husain, M., He, K., et al. (2019). Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a nonlinear predictor of patient outcomes in advanced cancers. *J. Cancer Res. Clin. Oncol.* 145, 2541–2546. doi: 10.1007/s00432-019-02982-4
- Li, X., Zhang, W., and Chen, K. (2019). Tumor mutation load and frequently mutated genes in gastric cancer-in reply. JAMA Oncol. 5, 577–578. doi: 10.1001/ jamaoncol.2019.0135
- Li, X., Pasche, B., Zhang, W., and Chen, K. (2018). Association of MUC16 mutation with tumor mutation load and outcomes in patients with gastric cancer. *JAMA Oncol.* 4, 1691–1698. doi: 10.1001/jamaoncol.2018.2805
- Li, Y., Guo, X. B., Wang, J. S., Wang, H. C., and Li, L. P. (2019). Function of fibroblast growth factor 2 in gastric cancer occurrence and prognosis. *Mol. Med. Rep.* 21, 575–582. doi: 10.3892/mmr.2019.10850
- Liang, L., Fang, J. Y., and Xu, J. (2016). Gastric cancer and gene copy number variation: emerging cancer drivers for targeted therapy. *Oncogene* 35, 1475– 1482. doi: 10.1038/onc.2015.209
- Long, G. V., Stroyakovskiy, D., Gogas, H., Levchenko, E., and Braud, F. D. (2015). Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAFmutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. *Lancet* 386, 444–451.
- Maleki Vareki, S. (2018). High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors. *J. Immuno Ther. Cancer* 6:157.
- Mao, Y., Feng, Q., Zheng, P., Yang, L., Liu, T., Xu, Y., et al. (2018). Low tumor purity is associated with poor prognosis, heavy mutation burden, and intense immune phenotype in colon cancer. *Cancer Manag. Res.* 10, 3569–3577. doi: 10.2147/CMAR.S171855

- Matsumoto, K., Umitsu, M., De Silva, D. M., Roy, A., and Bottaro, D. P. (2017). Hepatocyte growth factor/MET in cancer progression and biomarker discovery. *Cancer Sci.* 108, 296–307. doi: 10.1111/cas.13156
- Mukai, S., Oue, N., Oshima, T., Imai, T., Sekino, Y., Honma, R., et al. (2017). Overexpression of PCDHB9 promotes peritoneal metastasis and correlates with poor prognosis in patients with gastric cancer. J. Pathol. 243, 100–110. doi: 10.1002/path.4931
- Pan, J. H., Zhou, H., Cooper, L., Huang, J.-L., Zhu, S.-B., Zhao, X.-X., et al. (2019). LAYN is a prognostic biomarker and correlated with immune infiltrates in gastric and colon cancers. *Front. Immunol.* 10:6. doi: 10.3389/fimmu.2019. 00006
- Rhee, J. K., Jung, Y. C., Kim, K. R., Yoo, J., Kim, J., Lee, Y. J., et al. (2018). Impact of tumor purity on immune gene expression and clustering analyses across multiple cancer types. *Cancer Immunol. Res.* 6, 87–97. doi: 10.1158/2326-6066. CIR-17-0201
- Sakai, L. Y., Keene, D. R., Renard, M., and De Backer, J. (2016). FBN1: the diseasecausing gene for Marfan syndrome and other genetic disorders. *Gene* 591, 279–291. doi: 10.1016/j.gene.2016.07.033
- Sanchez-Vega, F., Mina, M., Armenia, J., Chatila, W. K., Luna, A., La, K. C., et al. (2018). Oncogenic signaling pathways in the cancer genome atlas. *Cell* 173, 321.e10–337.e10. doi: 10.1016/j.cell.2018.03.035
- Smyth, M. J., Ngiow, S. F., Ribas, A., and Teng, M. W. (2016). Combination cancer immunotherapies tailored to the tumour microenvironment. *Nat. Rev. Clin. Oncol.* 13, 143–158. doi: 10.1038/nrclinonc.2015.209
- Sullivan, R. J., Hamid, O., Gonzalez, R., Infante, J. R., Patel, M. R., Hodi, F. S., et al. (2019). Atezolizumab plus cobimetinib and vemurafenib in BRAFmutated melanoma patients. *Nat. Med.* 25, 929–935. doi: 10.1038/s41591-019-0474-7
- Tyner, J. W., Tognon, C. E., Bottomly, D., Wilmot, B., Kurtz, S. E., Savage, S. L., et al. (2018). Functional genomic landscape of acute myeloid leukaemia. *Nature* 562, 526–531. doi: 10.1038/s41586-018-0623-z
- van de Velde, C. J. (2008). Current role of surgery and multimodal treatment in localized gastric cancer. *Ann. Oncol.* 19(Suppl. 5), v93–v98. doi: 10.1093/ annonc/mdn319
- Wang, F., Wei, X. L., Wang, F. H., Xu, N., Shen, L., Dai, G. H., et al. (2019). Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432. Ann. Oncol. 30, 1479–1486. doi: 10.1093/annonc/mdz197
- Wang, J., Gao, P., Song, Y., Sun, J., Chen, X., Yu, H., et al. (2018). Prognostic value of gastric cancer-associated gene signatures: evidence based on a meta-analysis using integrated bioinformatics methods. J. Cell. Mol. Med. 22, 5743–5747. doi: 10.1111/jcmm.13823
- Wang, R., Deng, X., Yuan, C., Xin, H., Liu, G., Zhu, Y., et al. (2018). IFT80 improves invasion ability in gastric cancer cell line via ift80/p75NGFR/MMP9 signaling. *Int. J. Mol. Sci.* 19:3616. doi: 10.3390/ijms19113616
- Wang, W., Lou, W., Ding, B., Yang, B., Lu, H., Kong, Q., et al. (2019). A novel mRNA-miRNA-lncRNA competing endogenous RNA triple sub-network associated with prognosis of pancreatic cancer. *Aging* 11, 2610–2627. doi: 10. 18632/aging.101933
- Wang, Z., Martin, D., Molinolo, A. A., Patel, V., Iglesias-Bartolome, R., Degese, M. S., et al. (2014). mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations. *J. Natl. Cancer Inst.* 106:dju215. doi: 10.1093/jnci/dju215
- Yan, H. H. N., Siu, H. C., Law, S., Ho, S. L., Yue, S. S. K., Tsui, W. Y., et al. (2018). A comprehensive human gastric cancer organoid biobank captures tumor subtype heterogeneity and enables therapeutic screening. *Cell Stem Cell* 23, 882.e11–897.e11. doi: 10.1016/j.stem.2018.09.016
- Yoshihara, K., Shahmoradgoli, M., Martínez, E., Vegesna, R., Kim, H., Torres-Garcia, W., et al. (2013). Inferring tumour purity and stromal and immune cell admixture from expression data. *Nat. Commun.* 4:2612.
- Zeng, D., Li, M., Zhou, R., Zhang, J., Sun, H., Shi, M., et al. (2019). Tumor microenvironment characterization in gastric cancer identifies prognostic and immunotherapeutically relevant gene signatures. *Cancer Immunol. Res.* 7, 737– 750. doi: 10.1158/2326-6066.CIR-18-0436

- Zeng, D., Zhou, R., Yu, Y., Luo, Y., Zhang, J., Sun, H., et al. (2018). Gene expression profiles for a prognostic immunoscore in gastric cancer. *Br. J. Surg.* 105, 1338–1348. doi: 10.1002/bjs.10871
- Zhang, H., Deng, T., Liu, R., Bai, M., Zhou, L., Wang, X., et al. (2017). Exosome-delivered EGFR regulates liver microenvironment to promote gastric cancer liver metastasis. *Nat. Commun.* 8:15016. doi: 10.1038/ncomms 15016
- Zhang, Y., Gao, Y., Zhang, H., Zhang, J., He, F., Hnizda, A., et al. (2018). PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia. *Blood* 131, 2256–2261. doi: 10.1182/blood-2017-11-817510

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Li, Wang, Zhang, Wang and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.